A new type of gel made from seaweed-derived alginate can slowly release medicines like Vitamin B12 inside the body without damaging them, according to a 2026 laboratory study. Gram Research analysis shows the gel forms naturally at body temperature using a special catalyst, then releases medication in a controlled two-phase pattern with less initial burst and longer-lasting effects compared to standard gels—though human testing is still years away.
Scientists have created a new type of gel that forms naturally in the body and can slowly release medicines over time. According to Gram Research analysis, this alginate-based gel uses a special chemical process to form stable structures that protect sensitive medications like Vitamin B12 from breaking down. The gel can be customized by adjusting pH levels and using specific catalysts, allowing it to release medicine in a controlled, two-stage pattern that reduces the initial burst of medication while extending the overall release time. This breakthrough could lead to better drug delivery systems, fewer injections, and improved treatments for various medical conditions.
Key Statistics
A 2026 laboratory study published in Chemistry, an Asian Journal demonstrated that organocatalytically-tuned alginate hydrogels achieved sustained, biphasic Vitamin B12 release with reduced initial burst and prolonged release compared to conventional alginate matrices.
Research showed that anthranilic acid catalysis enabled efficient alginate-guanidine hydrazide gel formation at neutral pH, overcoming previous limitations of hydrazone chemistry that required acidic conditions incompatible with physiological environments.
The new gel formulation maintained Vitamin B12 integrity and bioactivity throughout the release process, demonstrating successful encapsulation of sensitive therapeutic payloads without cargo degradation.
The Quick Take
- What they studied: Whether a new type of gel made from alginate (a natural substance from seaweed) could safely hold and slowly release medicines in the body without damaging them.
- Who participated: This was a laboratory study testing the gel’s properties and its ability to carry Vitamin B12. No human or animal trials were conducted in this research.
- Key finding: The new gel successfully released Vitamin B12 in a controlled, two-phase pattern with less initial burst and longer-lasting release compared to standard alginate gels.
- What it means for you: This technology could eventually lead to medicines that work longer with fewer doses needed, though it’s still in early laboratory stages and years away from being available to patients.
The Research Details
Researchers created a new gel by combining two substances: oxidized alginate (a natural material from seaweed) and guanidine hydrazide (a chemical compound). They mixed these under controlled conditions using a special catalyst called anthranilic acid to speed up the gel-forming process. The team then tested how different conditions—like pH level (how acidic or basic the environment is) and which catalyst they used—affected how quickly the gel formed and how dense it became.
Once they perfected the gel recipe, they loaded it with Vitamin B12 to see if the gel could protect this sensitive vitamin and release it slowly over time. They measured how much vitamin was released at different time points to understand the release pattern. The entire study was conducted in laboratory conditions, not in living organisms.
This research approach is important because most drug-delivery gels require external triggers (like heat or light) to form and release medicine. This new gel forms naturally at body temperature and pH, making it more practical for medical use. The ability to customize the gel’s properties through different catalysts means doctors could eventually tailor treatments for specific patients or conditions.
This is a laboratory-based chemical and materials science study, not a clinical trial. The research demonstrates proof-of-concept for the gel’s formation and basic drug-carrying ability. However, the study did not test the gel in living systems, so safety and effectiveness in humans remain unknown. The findings are promising but represent early-stage research that requires additional testing before any medical applications.
What the Results Show
The new alginate-guanidine hydrazide gel successfully formed under mild, physiological conditions without requiring external triggers. The researchers found that using anthranilic acid as a catalyst was particularly effective, allowing the gel to form even at neutral pH (similar to body conditions), which overcomes a major limitation of previous hydrazone-based gels that required acidic environments.
When loaded with Vitamin B12, the gel demonstrated a two-phase release pattern: an initial slower release phase followed by a more sustained, prolonged release phase. This pattern is superior to conventional alginate gels, which typically show a large initial burst of medication followed by slower release. The controlled release meant that the Vitamin B12 remained stable and active throughout the process, indicating the gel successfully protected the sensitive cargo.
The team also discovered that adjusting the pH and catalyst selection gave them precise control over how quickly the gel formed and how tightly packed its structure was. More acidic conditions and specific catalysts created denser networks, which correlated with better control over medicine release rates.
The research showed that the minimum concentration of gel-forming material needed could be optimized through catalyst selection, potentially reducing the amount of material required for medical applications. The dynamic nature of the covalent bonds in the gel network suggested it could be responsive to changes in the body’s environment, opening possibilities for ‘smart’ gels that respond to specific triggers. The gel’s ability to maintain the integrity and bioactivity of Vitamin B12 suggests it could work with other sensitive medications as well.
Previous hydrazone-based gels typically required acidic conditions to form, limiting their use in the body where conditions are neutral. This new gel overcomes that limitation through organocatalytic tuning. Compared to conventional alginate gels, the new formulation provides superior control over release kinetics, reducing the problematic initial burst of medication that occurs with standard materials. The research builds on existing knowledge of alginate chemistry while introducing a novel catalyst approach that hadn’t been previously optimized for this application.
This study was conducted entirely in laboratory conditions using isolated gel samples and did not test the material in living organisms. Therefore, we don’t know how the gel would behave inside the human body, whether it would cause any immune reactions, or how long it would remain stable in physiological conditions. The study used only Vitamin B12 as a test medication, so we can’t confirm the gel works equally well with other drugs. The sample size and specific experimental replicates are not detailed in the abstract. Additionally, this research doesn’t address manufacturing scalability, cost, or regulatory pathway for eventual medical use.
The Bottom Line
This research is too early-stage to make clinical recommendations. It demonstrates promising laboratory results for a new drug-delivery platform, but requires extensive additional testing in animal models and eventually human trials before any medical applications. Confidence level: Low for clinical application; High for scientific merit and future potential.
Pharmaceutical researchers, biomedical engineers, and drug-delivery scientists should follow this technology’s development. Patients with conditions requiring frequent injections or medications that degrade easily may eventually benefit, but this is years away from clinical use. People should not expect this technology to be available for medical treatment in the near term.
This is fundamental research. Realistic timeline to clinical availability would be 5-10+ years, requiring animal testing, safety studies, manufacturing development, and regulatory approval before human trials could begin.
Frequently Asked Questions
How does this new gel release medicine differently than regular gels?
This gel releases medicine in two phases: slower initially, then sustained longer-term. Regular gels dump most medicine immediately (burst release), then slow down. The new gel’s controlled pattern means more consistent medicine levels in your body over time.
When will this gel technology be available for patients?
This is early laboratory research. Realistic timeline is 5-10+ years minimum, requiring animal testing, safety studies, and human trials before regulatory approval. It’s not available for medical use yet.
What makes this gel work at body temperature when other gels don’t?
The gel uses a special catalyst called anthranilic acid that speeds up the gel-forming chemical reaction at neutral pH and body temperature. Previous gels required acidic conditions incompatible with the body’s natural environment.
Could this gel work with medicines other than Vitamin B12?
The study only tested Vitamin B12, so we don’t know yet. The gel’s ability to protect sensitive molecules suggests it might work with other medications, but this requires additional research to confirm.
Is this gel safe to use in the human body?
Safety in humans is unknown—this study was laboratory-based only. Extensive animal testing and clinical trials would be required before determining safety and effectiveness in patients.
Want to Apply This Research?
- Once this technology reaches clinical use, users could track medication adherence by logging when sustained-release gel injections are administered and monitoring symptom improvement or biomarker levels over the extended release period.
- In the future, users could set reminders for less frequent medication administration (potentially monthly or quarterly instead of daily), reducing medication burden and improving compliance with treatment plans.
- Long-term tracking would involve monitoring medication effectiveness, side effects, and quality of life improvements compared to traditional daily medication schedules, with data shared between patient and healthcare provider.
This research represents early-stage laboratory science and has not been tested in living organisms or humans. The findings are promising but do not indicate that this technology is ready for medical use. Any potential clinical applications are years away and would require extensive additional testing, animal studies, and human trials before regulatory approval. This article is for informational purposes only and should not be interpreted as medical advice. Consult with healthcare providers before making any decisions about medications or treatments. The technology described is not currently available for patient use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
